Daratumumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Daratumumab comprises 436 peer-reviewed publications across 15 journals, 21 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Multiple Myeloma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Anemia, Hemolytic, and Amyloidosis. Most recent publication: A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study., Br J Haematol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
    Rajkumar SV, Dimopoulos MA, Palumbo A, et al. · Lancet Oncol · 2015
    PubMed: PMID 25439696 · NCT03792620 (MAXDARA) · Multiple Myeloma
  2. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
    Moreau P, Hulin C, Perrot A, et al. · Lancet Oncol · 2024
    PubMed: PMID 38889735 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  3. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
    Moreau P, Hulin C, Perrot A, et al. · Lancet Oncol · 2021
    PubMed: PMID 34529931 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  4. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
    Moreau P, Attal M, Hulin C, et al. · Lancet · 2019
    PubMed: PMID 31171419 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  5. Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.
    Manier S, Lambert J, Hulin C, et al. · Lancet Oncol · 2025
    PubMed: PMID 41038184 · NCT03993912 (IFM2017_03) · Multiple Myeloma
  6. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
    Lonial S, Weiss BM, Usmani SZ, et al. · Lancet · 2016
    PubMed: PMID 26778538 · NCT03792620 (MAXDARA) · Multiple Myeloma
  7. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.
    Giri S, Grimshaw A, Bal S, et al. · JAMA Oncol · 2022
    PubMed: PMID 32970151 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  8. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
    Berry DA, Zhou S, Higley H, et al. · JAMA Oncol · 2017
    PubMed: PMID 28494052 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02076009Multiple MyelomaProgression-free Survival (PFS)
From randomization to either disease progression or death whichever occurs first (up to 21 months)
Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)NA months
Lenalidomide, Low-dose Dexamethasone (Rd)18.43 months
NCT02136134Multiple MyelomaProgression-free Survival (PFS)
From the date of randomization to either progressive disease or death, whichever occurred first (approximately 1 year 4 months)
Bortezomib + Dexamethasone (Vd)7.16 months
Daratumumab + Bortezomib and Dexamethasone (DVd)NA months
NCT02195479Multiple MyelomaProgression Free Survival (PFS)
From randomization (Day -3) up to 2.4 years
Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)NA Months
Velcade, Melphalan and Prednisone (VMP)18.14 Months
NCT02252172Multiple MyelomaProgression-free Survival (PFS)
From randomization (Day -3) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)
Daratumumab + Lenalidomide + Dexamethasone (DRd)NA Months
Lenalidomide + Dexamethasone (Rd)31.87 Months
NCT02541383
Cassiopeia
Multiple MyelomaPost-Consolidation Stringent Complete Response (sCR) Rate
At day 100 post Autologous Stem Cell Transplant (ASCT), up to 114 days post ASCT
Arm A Part 1110 Participants
Arm B Part 1157 Participants
NCT02541383
Cassiopeia
Multiple MyelomaProgression Free Survival (PFS) Post Completion of Maintenance Therapy
From the date of second randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 35.4 months (cut-off for analysis was 26 months after the last rando 2 date).
Arm A Part 246.7 Months
Arm B Part 2NA Months
NCT03158688
CANDOR
Multiple MyelomaProgression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only)
From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks
Kd - Carfilzomib and Dexamethasone68 Participants
Kd - Carfilzomib and Dexamethasone86 Participants
KdD - Carfilzomib, Dexamethasone and Daratumumab202 Participants
KdD - Carfilzomib, Dexamethasone and Daratumumab110 Participants
NCT03180736
EMN14
Multiple MyelomaComparison of Progression Free Survival Between Treatment Arms (Daratumumab /Pomalidomide /Dexamethasone vs Pomalidomide / Dexamethasone)
PFS is assessed monthly from randomization until PD or death, whichever occurs first (approximately up to 3 years). PFS2 is assessed monthly from randomization until PD or death, whichever occurs first (approximately up to 5 years).
Daratumumab+Pomalidomide+Dexamethasone24.41 months
Daratumumab+Pomalidomide+Dexamethasone12.42 months
Pomalidomide + Dexamethasone6.93 months
Pomalidomide + Dexamethasone17.58 months
NCT03201965AmyloidosisPercentage of Participants With Overall Complete Hematologic Response (CHR)
Up to 2.4 years
CyBorD18.1 percentage of participants
Daratumumab Plus CyBorD53.3 percentage of participants
NCT03301220Smoldering Multiple MyelomaProgression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
From randomization (Day -5) up to 77 months
Arm A: Active Monitoring (ACTM)41.46 Months
Arm B: Daratumumab SCNA Months
NCT03357952Multiple MyelomaNumber of Participants With Dose Limiting Toxicity in Safety run-in Phase (Part 1)
Cycle 1 (28 days)
Part 1: Daratumumab + JNJ-637232830 Participants
NCT03357952Multiple MyelomaNumber of Participants With Treatment Emergent Adverse Events (TEAE) in Safety run-in Phase (Part 1)
Up to 2 years
Part 1: Daratumumab + JNJ-637232839 Participants
NCT03652064Multiple MyelomaFinal Progression-Free Survival (PFS) Analysis : Overall Minimal Residual Disease (MRD) Negative Rate
From randomization (Day 1) up to 64.8 months
Arm A: Bortezomib-lenalidomide-dexamethasone (VRd)39.4 Percentage of participants
Arm B: Daratumumab-bortezomib-lenalidomide-dexamethasone (D-VRd)60.9 Percentage of participants
NCT03652064Multiple MyelomaPrimary Analysis: Overall Minimal Residual Disease (MRD) Negative Rate
From randomization (Day 1) up to 27.9 months
Arm A: Bortezomib-lenalidomide-dexamethasone (VRd)35.4 Percentage of participants
Arm B: Daratumumab-bortezomib-lenalidomide-dexamethasone (D-VRd)53.3 Percentage of participants
NCT03710603
Perseus
Multiple MyelomaProgression Free Survival (PFS)
From the date of randomization to either progressive disease or death whichever occurred first, up to a maximum follow-up time of 54.41 months.
Daratumumab + VRd (D-VRd)50 Participants
Velcade Lenalidomide Dexamethasone (VRd)103 Participants
NCT03901963
AURIGA
Multiple MyelomaPercentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS)
From randomization up to 12 months
Daratumumab + Lenalidomide50.5 percentage of participants
Lenalidomide18.8 percentage of participants
NCT04181827
CARTITUDE-4
Multiple MyelomaProgression Free Survival (PFS)
From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)
Arm A: Standard Therapy: PVd or DPd11.79 months
Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])NA months
NCT04246047
DREAMM 7
Multiple MyelomaProgression-free Survival (PFS)
Up to approximately 41 months
Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)36.6 Months
Daratumumab + Bor + Dex13.4 Months
NCT04649060
LIGHTHOUSE
Multiple MyelomaProgression Free Survival (PFS)
From the date of randomization until the end of study (approximately 12 months).
Arm A (Melflufen+Dexamethasone+Daratumumab)NA months
Arm B (Daratumumab)4.86 months
NCT06868654
DREAMM 7
Multiple MyelomaProgression-free Survival (PFS)
Up to approximately 32 months
Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)NA Months
Daratumumab + Bor + Dex8.4 Months
NCT06868667
DREAMM 7
Multiple MyelomaProgression-free Survival (PFS)
Up to approximately 32 months
Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)NA Months
Daratumumab + Bor + Dex11.1 Months

Publications by year

1975–2026: 436 publications.

1975
1
1976
1
1980
1
1983
1
1985
1
1986
1
1987
2
1990
1
1992
2
1994
2
1995
1
1997
1
1998
1
1999
1
2000
1
2001
4
2002
3
2003
3
2004
3
2005
2
2006
4
2007
8
2008
9
2009
2
2010
14
2011
14
2012
15
2013
10
2014
13
2015
18
2016
13
2017
21
2018
12
2019
22
2020
38
2021
52
2022
31
2023
29
2024
27
2025
38
2026
13

Publications by indication

Multiple Myeloma (282)

  • A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study.
    Br J Haematol · 2026 · PMID 42097596 · NCT03757221
  • Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)-a trial by Asian Myeloma Network (NCT03695744).
    Leuk Lymphoma · 2026 · PMID 41400977 · NCT03695744
  • Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.
    Blood · 2026 · PMID 41100731 · NCT06768489
  • Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.
    Blood · 2026 · PMID 40983035 · NCT04151667
  • Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.
    Adv Ther · 2026 · PMID 41627370 · NCT04181827

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (40)

  • Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.
    Leuk Lymphoma · 2022 · PMID 34151693 · NCT07021677
  • Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.
    JAMA Oncol · 2022 · PMID 32970151 · NCT07021677
  • Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.
    Haematologica · 2022 · PMID 35021604 · NCT07021677
  • Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    J Immunother Cancer · 2021 · PMID 32439800 · NCT07021677
  • Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol.
    Blood Adv · 2021 · PMID 33635331 · NCT07021677

Anemia, Hemolytic (12)

  • Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review.
    Blood Adv · 2021 · PMID 32119735 · NCT05004259
  • Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.
    Blood Adv · 2020 · PMID 31235526 · NCT05004259
  • Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia.
    Pediatr Blood Cancer · 2020 · PMID 31544339 · NCT05004259
  • Post-allogeneic transplant Evans syndrome successfully treated with daratumumab.
    Br J Haematol · 2020 · PMID 31441030 · NCT05004259
  • Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.
    Blood Adv · 2019 · PMID 30291113 · NCT05004259

Amyloidosis (4)

  • Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.
    Blood · 2026 · PMID 42118698 · NCT03201965
  • Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
    Ann Hematol · 2023 · PMID 36862168 · NCT03201965
  • Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
    JACC CardioOncol · 2023 · PMID 36444227 · NCT03201965
  • Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    N Engl J Med · 2021 · PMID 34192431 · NCT03201965

Neoplasms, Plasma Cell (3)

  • Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Clin Chem Lab Med · 2022 · PMID 34392637 · NCT03184194
  • Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.
    Breast · 2022 · PMID 36223695 · NCT07075510
  • Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins.
    J Control Release · 2021 · PMID 34186147 · NCT07075510

Immunoglobulin Light-chain Amyloidosis (2)

  • AL Amyloidosis: Current Treatment and Outcomes.
    Adv Hematol · 2025 · PMID 40226119 · NCT04270175
  • Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
    Blood · 2020 · PMID 31978210 · NCT02841033

Publications by journal

Trial-results highlights

Several pivotal trials have investigated **Daratumumab** in the treatment of multiple myeloma. In NCT02076009, the median progression-free survival (PFS) was **18.43 months** for the lenalidomide and low-dose dexamethasone (Rd) arm. Another multiple myeloma trial, NCT02136134, reported a median PFS of **7.16 months** for the bortezomib and dexamethasone (Vd) arm. In NCT02195479, the velcade, melphalan, and prednisone (VMP) arm had a median PFS of **18.14 months**. The NCT02252172 study, also for multiple myeloma, showed a median PFS of **31.87 months** for the lenalidomide and dexamethasone (Rd) arm.

The NCT02541383 (Cassiopeia) trial for multiple myeloma reported participant counts for the post-consolidation stringent complete response (sCR) rate at day 100 post-Autologous Stem Cell Transplant (ASCT). Arm A Part 1 included **110 participants**, and Arm B Part 1 included **157 participants**. For progression-free survival (PFS) post-completion of maintenance therapy, Arm A Part 2 reported a median of **46.7 months**. In the NCT03158688 (CANDOR) study for multiple myeloma, participant counts for the progression-free survival endpoint were:

  • Kd (Carfilzomib and Dexamethasone): 68 participants and 86 participants
  • KdD (Carfilzomib, Dexamethasone, and **Daratumumab**): 202 participants and 110 participants

The NCT03180736 (EMN14) trial, investigating multiple myeloma, reported a median progression-free survival (PFS) of **24.41 months** for the **Daratumumab** + Pomalidomide + Dexamethasone arm, compared to **6.93 months** for the Pomalidomide + Dexamethasone arm. For PFS2, the **Daratumumab** + Pomalidomide + Dexamethasone arm reported a median of **12.42 months**, and the Pomalidomide + Dexamethasone arm reported a median of **17.58 months**.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Daratumumab publications (436)

2026 (13 papers)

  1. A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study.
    Bobin A, Macro M, Touzeau C, et al. · Br J Haematol · 2026 · Trial result
    PubMed: PMID 42097596 · NCT03757221 (IDARA) · Multiple Myeloma
  2. NAD+‒circadian rhythm coupling in dementia.
    Zhang SQ, Lee J, Pan JP, et al. · Alzheimers Dement · 2026 · Derived
    PubMed: PMID 42063312 · NCT04070378 (DARZAD) · Alzheimer Disease
  3. Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)-a trial by Asian Myeloma Network (NCT03695744).
    Tan MSY, Nagarajan C, Ooi M, et al. · Leuk Lymphoma · 2026 · Derived
    PubMed: PMID 41400977 · NCT03695744 · Multiple Myeloma
  4. Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.
    Pillarisetti K, Yang D, Luistro L, et al. · Blood · 2026 · Derived
    PubMed: PMID 41100731 · NCT06768489 · Multiple Myeloma
  5. CD38 overexpression drives glioblastoma progression via L1CAM/ICAM1/JAK-STAT-Driven tumor microenvironment rewiring.
    Norouzi S, Aulakh S · Transl Oncol · 2026 · Derived
    PubMed: PMID 41946147 · NCT04922723 (PRIDE) · Glioblastoma
  6. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.
    Meads MB, Zhao X, Noyes D, et al. · Blood · 2026 · Derived
    PubMed: PMID 40983035 · NCT04151667 · Multiple Myeloma
  7. Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.
    Lopez-Muñoz N, Bar N, Diels J, et al. · Adv Ther · 2026 · Derived
    PubMed: PMID 41627370 · NCT04181827 (CARTITUDE-4) · Multiple Myeloma
  8. Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.
    Kastritis E, Palladini G, Minnema MC, et al. · Blood · 2026 · Derived
    PubMed: PMID 42118698 · NCT03201965 · Amyloidosis
  9. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.
    Einsele H, San-Miguel J, Dhakal B, et al. · Lancet Oncol · 2026 · Derived
    PubMed: PMID 41519141 · NCT04181827 (CARTITUDE-4) · Multiple Myeloma
  10. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
    Costa LJ, Bahlis NJ, Perrot A, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41363801 · NCT05083169 (MajesTEC-3) · Multiple Myeloma
  11. Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.
    Chen Y, Hua Z, Xu Y, et al. · EClinicalMedicine · 2026 · Derived
    PubMed: PMID 41940000 · NCT05562882 · Purpura, Thrombocytopenic, Idiopathic
  12. Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.
    Bertamini L, Fokkema C, Rodriguez-Otero P, et al. · Blood · 2026 · Derived
    PubMed: PMID 41060326 · NCT03710603 (Perseus) · Multiple Myeloma
  13. Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE.
    Bahlis NJ, Facon T, San-Miguel JF, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 42085642 · NCT02252172 · Multiple Myeloma

2025 (38 papers)

  1. Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.
    Manier S, Lambert J, Hulin C, et al. · Lancet Oncol · 2025 · Trial result
    PubMed: PMID 41038184 · NCT03993912 (IFM2017_03) · Multiple Myeloma
  2. A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
    Voorhees PM, Sborov DW, Laubach J, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 39452950 · NCT02874742 · Multiple Myeloma
  3. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
    Usmani SZ, Facon T, Hungria V, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 39910273 · NCT03652064 · Multiple Myeloma
  4. Safety and efficacy of daratumumab in immune thrombocytopenia.
    Tsykunova G, Holme PA, Tran HTT, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40763272 · NCT04703621
  5. Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.
    Touzeau C, Lipe B, Khan AM, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 40768190 · NCT04181827 (CARTITUDE-4) · Multiple Myeloma
  6. Intestinal Perforation Secondary to Bortezomib-Induced Autonomic Neuropathy.
    Sánchez Salas JA, Moreno Belmonte MJ, Poveda García A, et al. · Clin Case Rep · 2025 · Derived
    PubMed: PMID 40171013 · NCT03710603 (Perseus) · Multiple Myeloma
  7. Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma.
    Rata M, Blackledge M, Scurr E, et al. · Insights Imaging · 2025 · Derived
    PubMed: PMID 35900614 · NCT03188172 (MUKnineb) · Multiple Myeloma
  8. Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.
    Perrot A, Facon T, Plesner T, et al. · Eur J Haematol · 2025 · Derived
    PubMed: PMID 39952901 · NCT02252172 · Multiple Myeloma
  9. Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.
    Paul B, Minarik J, Cottini F, et al. · EJHaem · 2025 · Derived
    PubMed: PMID 40485906 · NCT04892446 · Multiple Myeloma
  10. Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
    Moreau P, Facon T, Usmani SZ, et al. · Leukemia · 2025 · Derived
    PubMed: PMID 39815052 · NCT02252172 · Multiple Myeloma
  11. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
    Mina R, Mylin AK, Yokoyama H, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 39756844 · NCT04181827 (CARTITUDE-4) · Multiple Myeloma
  12. Targeting CD38 in Antibody-Mediated Rejection.
    Mayer KA, Budde K, Diebold M, et al. · Transpl Int · 2025 · Derived
    PubMed: PMID 40444214 · NCT05913596
  13. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.
    Mateos MV, Trudel S, Quach H, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40763276 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  14. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.
    Mateos MV, San-Miguel J, Cavo M, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 40220771 · NCT02195479 · Multiple Myeloma
  15. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.
    Mateos MV, Paiva B, Cedena MT, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 40769684 · NCT03742297
  16. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma.
    Lonial S, Dimopoulos MA, Berdeja JG, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 40346992 · NCT04975997 (EXCALIBER-RRMM) · Multiple Myeloma
  17. AL Amyloidosis: Current Treatment and Outcomes.
    Locke M, Nieto M · Adv Hematol · 2025 · Derived
    PubMed: PMID 40226119 · NCT04270175 · Immunoglobulin Light-chain Amyloidosis
  18. Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.
    Landgren O, Chari A, Cohen YC, et al. · Blood · 2025 · Derived
    PubMed: PMID 39652826 · NCT02316106 · Multiple Myeloma
  19. Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.
    Kraeber-Bodéré F, Jamet B, Zweegman S, et al. · Blood · 2025 · Derived
    PubMed: PMID 40991848 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  20. Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study.
    Keaveney S, Dragan A, Rata M, et al. · Insights Imaging · 2025 · Derived
    PubMed: PMID 37840055 · NCT03188172 (MUKnineb) · Multiple Myeloma
  21. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
    Hungria V, Robak P, Hus M, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 40680754 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  22. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
    Hungria V, Hus M, Fu C, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 40680752 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  23. CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.
    Harrison SJ, Touzeau C, Kint N, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39938094 · NCT04181827 (CARTITUDE-4) · Multiple Myeloma
  24. Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study).
    Glöckner A, Schönland S, Einsele H, et al. · BMC Cancer · 2025 · Derived
    PubMed: PMID 39865222 · NCT05675319 (AlloRelapseMM) · Multiple Myeloma
  25. Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.
    Gao Z, Pan H, Zhang L, et al. · Blood · 2025 · Derived
    PubMed: PMID 40331918 · NCT05832216 · Anemia, Aplastic
  26. Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.
    Fu W, Bang SM, Huang H, et al. · Ann Hematol · 2025 · Derived
    PubMed: PMID 40407887 · NCT03217812 · Multiple Myeloma
  27. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.
    Fu W, Bang SM, Huang H, et al. · Ann Hematol · 2025 · Derived
    PubMed: PMID 39227450 · NCT03217812 · Multiple Myeloma
  28. Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting.
    Fonseca R, Diels J, Ghilotti F, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 40613875 · NCT04181827 (CARTITUDE-4) · Multiple Myeloma
  29. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.
    Facon T, Moreau P, Weisel K, et al. · Leukemia · 2025 · Derived
    PubMed: PMID 40016302 · NCT02252172 · Multiple Myeloma
  30. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
    Dimopoulos MA, Voorhees PM, Schjesvold F, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39652675 · NCT03301220 · Smoldering Multiple Myeloma
  31. Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma.
    de Queiroz Crusoé E, Leal Ribeiro Dos Santos JS, de Andrade Santos J, et al. · Blood Neoplasia · 2025 · Derived
    PubMed: PMID 40575076 · NCT03792620 (MAXDARA) · Multiple Myeloma
  32. Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.
    Corre J, Vincent L, Moreau P, et al. · Blood · 2025 · Derived
    PubMed: PMID 40127397 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  33. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.
    Chari A, van de Donk NWCJ, Dholaria B, et al. · Blood · 2025 · Derived
    PubMed: PMID 40983036 · NCT04108195 · Multiple Myeloma
  34. MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.
    Bhutani M, Robinson M, Foureau D, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39576965 · NCT04113018 · Multiple Myeloma
  35. Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.
    Bhatia S, Topalian SL, Sharfman W, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39889250 · NCT02488759 (CheckMate358)
  36. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.
    Badros A, Foster L, Anderson LD, et al. · Blood · 2025 · Derived
    PubMed: PMID 39331724 · NCT03901963 (AURIGA) · Multiple Myeloma
  37. Targeting B Cells and Plasma Cells in Glomerular Disease.
    Ahmad SB, Jefferson JA · J Am Soc Nephrol · 2025 · Derived
    PubMed: PMID 40465397 · NCT04810754 (DARALUP) · Lupus Erythematosus, Systemic
  38. Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial.
    Weisel K, Mateos MV, Landgren O, et al. · Clin Lymphoma Myeloma Leuk · 2025 · Background
    PubMed: PMID 40087058 · NCT03158688 (CANDOR) · Multiple Myeloma

2024 (27 papers)

  1. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
    Moreau P, Hulin C, Perrot A, et al. · Lancet Oncol · 2024 · Trial result
    PubMed: PMID 38889735 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  2. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
    White D, Schiller GJ, Madan S, et al. · Front Oncol · 2024 · Derived
    PubMed: PMID 38826786 · NCT02343042 (STOMP) · Multiple Myeloma
  3. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
    Touzeau C, Perrot A, Hulin C, et al. · Blood · 2024 · Derived
    PubMed: PMID 38394666 · NCT03606577 (IFM 2018-04) · Multiple Myeloma
  4. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
    Spencer A, Moreau P, Mateos MV, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38048391 · NCT02136134 · Multiple Myeloma
  5. A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
    Sonneveld P, Dimopoulos MA, Boccadoro M, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 39287147 · NCT02874742 · Multiple Myeloma
  6. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Sonneveld P, Dimopoulos MA, Boccadoro M, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38084760 · NCT03710603 (Perseus) · Multiple Myeloma
  7. Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
    Silbermann R, Laubach J, Kaufman JL, et al. · Am J Hematol · 2024 · Derived
    PubMed: PMID 38622840 · NCT02874742 · Multiple Myeloma
  8. Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
    San-Miguel J, Dhakal B, Patel N, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 39110421 · NCT04181827 (CARTITUDE-4) · Multiple Myeloma
  9. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
    Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 38651976 · NCT03651128 (KarMMa-3) · Multiple Myeloma
  10. Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab.
    Qing M, Zhou T, Perova T, et al. · Ann Hematol · 2024 · Derived
    PubMed: PMID 38233570 · NCT02927925 · Lymphoma
  11. Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma.
    Pulliam T, Jani S, Jing L, et al. · Cell Rep Med · 2024 · Derived
    PubMed: PMID 38340723 · NCT02488759 (CheckMate358)
  12. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
    Pour L, Szarejko M, Bila J, et al. · Haematologica · 2024 · Derived
    PubMed: PMID 37646660 · NCT04649060 (LIGHTHOUSE) · Multiple Myeloma
  13. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.
    Overman MJ, Gelsomino F, Aglietta M, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38821718 · NCT02060188 (CheckMate142)
  14. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
    Ocio EM, Efebera YA, Hájek R, et al. · Haematologica · 2024 · Derived
    PubMed: PMID 37646657 · NCT04649060 (LIGHTHOUSE) · Multiple Myeloma
  15. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
    Oaknin A, Moore K, Meyer T, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 38608691 · NCT02488759 (CheckMate358)
  16. Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study.
    Kumar L, Melinkeri S, Ganesan P, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 38116642 · NCT03768960 · Multiple Myeloma
  17. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Hungria V, Robak P, Hus M, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38828933 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  18. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
    Delimpasi S, Dimopoulos MA, Straub J, et al. · Am J Hematol · 2024 · Derived
    PubMed: PMID 38856176 · NCT03439293 · Multiple Myeloma
  19. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
    Chari A, Kaufman JL, Laubach J, et al. · Blood Cancer J · 2024 · Derived
    PubMed: PMID 38977707 · NCT02874742 · Multiple Myeloma
  20. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
    Callander NS, Silbermann R, Kaufman JL, et al. · Blood Cancer J · 2024 · Derived
    PubMed: PMID 38649340 · NCT02874742 · Multiple Myeloma
  21. Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study.
    Bhatla T, Hogan LE, Teachey DT, et al. · Blood · 2024 · Derived
    PubMed: PMID 39158071 · NCT03384654 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  22. Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010).
    An G, Ge Z, Jing H, et al. · Blood Sci · 2024 · Derived
    PubMed: PMID 38832105 · NCT04121260 · Multiple Myeloma
  23. Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
    Amatangelo M, Flynt E, Stong N, et al. · Cell Rep Med · 2024 · Derived
    PubMed: PMID 38776914 · NCT02773030 · Multiple Myeloma
  24. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.
    Almansour SA, Alqudah MAY, Abuhelwa Z, et al. · Ther Adv Med Oncol · 2024 · Derived
    PubMed: PMID 39229471 · NCT02136134 · Multiple Myeloma
  25. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
    Ailawadhi S, Arnulf B, Patel K, et al. · Blood · 2024 · Derived
    PubMed: PMID 39197072 · NCT03651128 (KarMMa-3) · Multiple Myeloma
  26. Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy.
    Adhikarla V, Awuah D, Caserta E, et al. · Front Immunol · 2024 · Derived
    PubMed: PMID 38698840 · NCT05363111 · Multiple Myeloma
  27. Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma.
    Abdallah N, Kumar SK · J Natl Compr Canc Netw · 2024 · Derived
    PubMed: PMID 39536451 · NCT03652064 · Multiple Myeloma

2023 (29 papers)

  1. Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
    Wong S, Hamidi H, Costa LJ, et al. · Front Immunol · 2023 · Derived
    PubMed: PMID 37559718 · NCT02431208 · Multiple Myeloma
  2. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
    Voorhees PM, Sborov DW, Laubach J, et al. · Lancet Haematol · 2023 · Derived
    PubMed: PMID 37708911 · NCT02874742 · Multiple Myeloma
  3. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
    Suzuki K, Wechalekar AD, Kim K, et al. · Ann Hematol · 2023 · Derived
    PubMed: PMID 36862168 · NCT03201965 · Amyloidosis
  4. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
    Sonneveld P, Chanan-Khan A, Weisel K, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36413710 · NCT02136134 · Multiple Myeloma
  5. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
    Schiller GJ, Lipe BC, Bahlis NJ, et al. · Clin Lymphoma Myeloma Leuk · 2023 · Derived
    PubMed: PMID 37393120 · NCT02343042 (STOMP) · Multiple Myeloma
  6. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
    San-Miguel J, Dhakal B, Yong K, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37272512 · NCT04181827 (CARTITUDE-4) · Multiple Myeloma
  7. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
    Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 36762851 · NCT03651128 (KarMMa-3) · Multiple Myeloma
  8. A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
    Nooka AK, Kaufman JL, Rodriguez C, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 36799429 · NCT02874742 · Multiple Myeloma
  9. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.
    Nahi H, Usmani SZ, Mateos MV, et al. · Leuk Lymphoma · 2023 · Derived
    PubMed: PMID 36593729 · NCT02519452 · Multiple Myeloma
  10. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
    Moreau P, Chari A, Oriol A, et al. · Blood Cancer J · 2023 · Derived
    PubMed: PMID 36882409 · NCT03412565 · Multiple Myeloma
  11. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
    Minnema MC, Dispenzieri A, Merlini G, et al. · JACC CardioOncol · 2023 · Derived
    PubMed: PMID 36444227 · NCT03201965 · Amyloidosis
  12. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
    Maura F, Boyle EM, Coffey D, et al. · Nat Cancer · 2023 · Derived
    PubMed: PMID 37945755 · NCT03290950 · Multiple Myeloma
  13. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
    Mateos MV, Rigaudeau S, Basu S, et al. · J Oncol Pharm Pract · 2023 · Derived
    PubMed: PMID 36067063 · NCT02252172 · Multiple Myeloma
  14. Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma.
    Li X, Dosne AG, Pérez Ruixo C, et al. · Clin Pharmacokinet · 2023 · Derived
    PubMed: PMID 37022569 · NCT01985126 · Multiple Myeloma
  15. Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study.
    Kraeber-Bodéré F, Zweegman S, Perrot A, et al. · Haematologica · 2023 · Derived
    PubMed: PMID 36263839 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  16. Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
    Kastritis E, Terpos E, Symeonidis A, et al. · Am J Hematol · 2023 · Derived
    PubMed: PMID 37340832 · NCT03450057 (DARE) · Multiple Myeloma
  17. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
    Kaiser MF, Hall A, Walker K, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37315268 · NCT03188172 (MUKnineb) · Multiple Myeloma
  18. Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.
    Fu W, Li W, Hu J, et al. · Clin Lymphoma Myeloma Leuk · 2023 · Derived
    PubMed: PMID 36402700 · NCT03234972 · Multiple Myeloma
  19. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
    Fu W, Bang SM, Huang H, et al. · Clin Lymphoma Myeloma Leuk · 2023 · Derived
    PubMed: PMID 37024420 · NCT03217812 · Multiple Myeloma
  20. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
    Facon T, Kumar SK, Plesner T, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 37212642 · NCT02252172 · Multiple Myeloma
  21. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
    Dimopoulos MA, Terpos E, Boccadoro M, et al. · Lancet Haematol · 2023 · Derived
    PubMed: PMID 37793772 · NCT03180736 (EMN14) · Multiple Myeloma
  22. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
    Dimopoulos MA, Oriol A, Nahi H, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36599114 · NCT02076009 · Multiple Myeloma
  23. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
    Derman BA, Zonder J, Reece D, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 36763537 · NCT01665794 · Multiple Myeloma
  24. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
    de Botton S, Cluzeau T, Vigil C, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 36477975 · NCT02807558 · Leukemia, Myeloid, Acute
  25. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
    Cohen AD, Mateos MV, Cohen YC, et al. · Blood · 2023 · Derived
    PubMed: PMID 36095849 · NCT04133636 (CARTITUDE-2) · Multiple Myeloma
  26. Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment.
    Angeletti A, Bruschi M, Kajana X, et al. · Front Immunol · 2023 · Derived
    PubMed: PMID 37705972 · NCT05704400 · Nephrotic Syndrome
  27. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group.
    Wechalekar AD, Cibeira MT, Gibbs SD, et al. · Amyloid · 2023 · Background
    PubMed: PMID 35838162 · NCT06297681
  28. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study.
    Usmani SZ, Quach H, Mateos MV, et al. · Blood Adv · 2023 · Background
    PubMed: PMID 37163358 · NCT03158688 (CANDOR) · Multiple Myeloma
  29. A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
    Paul B, Liedtke M, Khouri J, et al. · Future Oncol · 2023 · Background
    PubMed: PMID 36779512 · NCT04892446 · Multiple Myeloma

2022 (31 papers)

  1. Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.
    Mirgh S, Sharma A, Folbs B, et al. · Leuk Lymphoma · 2022 · Trial result
    PubMed: PMID 34151693 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.
    Giri S, Grimshaw A, Bal S, et al. · JAMA Oncol · 2022 · Trial result
    PubMed: PMID 32970151 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  3. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.
    Cerrano M, Bonifacio M, Olivi M, et al. · Haematologica · 2022 · Trial result
    PubMed: PMID 35021604 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  4. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
    Yimer H, Melear J, Faber E, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 35730586 · NCT02951819 · Multiple Myeloma
  5. Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.
    Usmani SZ, Khan I, Chiu C, et al. · Exp Hematol Oncol · 2022 · Derived
    PubMed: PMID 29445583 · NCT01985126 · Multiple Myeloma
  6. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.
    Swan D, Henderson R, McEllistrim C, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 35985959 · NCT03901963 (AURIGA) · Multiple Myeloma
  7. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
    Sborov DW, Baljevic M, Reeves B, et al. · Br J Haematol · 2022 · Derived
    PubMed: PMID 36111391 · NCT02874742 · Multiple Myeloma
  8. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
    San-Miguel J, Avet-Loiseau H, Paiva B, et al. · Blood · 2022 · Derived
    PubMed: PMID 34269818 · NCT02252172 · Multiple Myeloma
  9. Is it time to tailor treatment on the basis of minimal residual disease in multiple myeloma?
    Oliva S, Kaiser MF · Lancet Haematol · 2022 · Derived
    PubMed: PMID 34826409 · NCT03188172 (MUKnineb) · Multiple Myeloma
  10. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S, Verkleij CPM, Zajec M, et al. · Clin Chem Lab Med · 2022 · Derived
    PubMed: PMID 34392637 · NCT03184194 · Neoplasms, Plasma Cell
  11. The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
    Nakamura A, Grossman S, Song K, et al. · Blood · 2022 · Derived
    PubMed: PMID 35226739 · NCT04776018
  12. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
    Mohan M, Gundarlapalli S, Szabo A, et al. · Am J Hematol · 2022 · Derived
    PubMed: PMID 35285981 · NCT04140162 · Multiple Myeloma
  13. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
    Miyazaki T, Maiti M, Hennessy M, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34001523 · NCT04136756 · Multiple Myeloma
  14. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
    Mateos MV, Dimopoulos MA, Cavo M, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 34344638 · NCT02195479 · Multiple Myeloma
  15. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
    Lu J, Fu W, Li W, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 34108127 · NCT03234972 · Multiple Myeloma
  16. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
    Lonial S, Popat R, Hulin C, et al. · Lancet Haematol · 2022 · Derived
    PubMed: PMID 36209764 · NCT02773030 · Multiple Myeloma
  17. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ, Van Cutsem E, Luisa Limon M, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34637336 · NCT02060188 (CheckMate142)
  18. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
    Jing H, Yang L, Qi J, et al. · Ann Hematol · 2022 · Derived
    PubMed: PMID 36301338 · NCT02852837 · Multiple Myeloma
  19. Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
    He J, Berringer H, Heeg B, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 35876974 · NCT02136134 · Multiple Myeloma
  20. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
    Cavo M, San-Miguel J, Usmani SZ, et al. · Blood · 2022 · Derived
    PubMed: PMID 34289038 · NCT02136134 · Multiple Myeloma
  21. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
    Bahlis NJ, Siegel DS, Schiller GJ, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 35133221 · NCT01946477 (POM MM 014) · Multiple Myeloma
  22. Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.
    Alberge JB, Kraeber-Bodéré F, Jamet B, et al. · J Nucl Med · 2022 · Derived
    PubMed: PMID 35086897 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  23. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ, Quach H, Mateos MV, et al. · Lancet Oncol · 2022 · Background
    PubMed: PMID 34871550 · NCT03158688 (CANDOR) · Multiple Myeloma
  24. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.
    Siegel D, Weisel K, Zahlten-Kumeli A, et al. · Leuk Lymphoma · 2022 · Background
    PubMed: PMID 34180331 · NCT03158688 (CANDOR) · Multiple Myeloma
  25. FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
    Sharma P, Kanapuru B, George B, et al. · Clin Cancer Res · 2022 · Background
    PubMed: PMID 35046063 · NCT05849610 (GEM-TECTAL)
  26. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
    Sanchorawala V, Palladini G, Minnema MC, et al. · Am J Hematol · 2022 · Background
    PubMed: PMID 35293006 · NCT06297681
  27. Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.
    Reinisch M, Untch M, Mahlberg R, et al. · Breast · 2022 · Background
    PubMed: PMID 36223695 · NCT07075510 · Neoplasms, Plasma Cell
  28. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
    Landgren O, Weisel K, Rosinol L, et al. · Br J Haematol · 2022 · Background
    PubMed: PMID 35608261 · NCT03158688 (CANDOR) · Multiple Myeloma
  29. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
    Hayden PJ, Roddie C, Bader P, et al. · Ann Oncol · 2022 · Background
    PubMed: PMID 34923107 · NCT05849610 (GEM-TECTAL)
  30. Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma.
    Frerichs KA, Minnema MC, Levin MD, et al. · Blood Adv · 2022 · Background
    PubMed: PMID 34625791 · NCT04700176 · Multiple Myeloma
  31. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
    Dimopoulos MA, Moreau P, Terpos E, et al. · Hemasphere · 2022 · Background
    PubMed: PMID 33554050 · NCT05849610 (GEM-TECTAL)

2021 (52 papers)

  1. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    Tembhare PR, Sriram H, Khanka T, et al. · J Immunother Cancer · 2021 · Trial result
    PubMed: PMID 32439800 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol.
    Rajendra A, Jain H, Bonda VNA, et al. · Blood Adv · 2021 · Trial result
    PubMed: PMID 33635331 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  3. Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab.
    Punatar S, Gokarn A, Nayak L, et al. · Am J Blood Res · 2021 · Trial result
    PubMed: PMID 34824885 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  4. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
    Palladini G, Kastritis E, Maurer MS, et al. · Blood · 2021 · Trial result
    PubMed: PMID 32244252 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  5. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
    Moreau P, Hulin C, Perrot A, et al. · Lancet Oncol · 2021 · Trial result
    PubMed: PMID 34529931 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  6. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
    Michaleas S, Penninga E, Hovgaard D, et al. · Oncologist · 2021 · Trial result
    PubMed: PMID 33026700 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  7. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia.
    Jeyaraman P, Borah P, Rajput P, et al. · Blood Cells Mol Dis · 2021 · Trial result
    PubMed: PMID 32653327 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  8. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study.
    Huang H, Zhu J, Yao M, et al. · J Hematol Oncol · 2021 · Trial result
    PubMed: PMID 33588922 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  9. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N, Zugmaier G, Dombret H, et al. · Leuk Lymphoma · 2021 · Trial result
    PubMed: PMID 32619115 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  10. Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia.
    Cerrano M, Castella B, Lia G, et al. · Br J Haematol · 2021 · Trial result
    PubMed: PMID 32686081 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  11. Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits.
    Zand L, Rajkumar SV, Leung N, et al. · J Am Soc Nephrol · 2021 · Derived
    PubMed: PMID 33685975 · NCT03095118 · Glomerulonephritis, Membranoproliferative
  12. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
    Weisel K, Spencer A, Lentzsch S, et al. · J Hematol Oncol · 2021 · Derived
    PubMed: PMID 32819447 · NCT02136134 · Multiple Myeloma
  13. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.
    Voorhees PM, Rodriguez C, Reeves B, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 33606004 · NCT02874742 · Multiple Myeloma
  14. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM, Kaufman JL, Laubach J, et al. · Blood · 2021 · Derived
    PubMed: PMID 32325490 · NCT02874742 · Multiple Myeloma
  15. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
    Topalian SL, Bhatia S, Amin A, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32324435 · NCT02488759 (CheckMate358)
  16. Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.
    Shah N, Perales MA, Turtle CJ, et al. · Future Oncol · 2021 · Derived
    PubMed: PMID 34154392 · NCT04136756 · Multiple Myeloma
  17. Daratumumab in T-cell acute lymphoblastic leukaemia: A case report and review of the literature.
    Ruhayel SD, Valvi S · Pediatr Blood Cancer · 2021 · Derived
    PubMed: PMID 33245179 · NCT03384654 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  18. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
    Plesner T, Dimopoulos MA, Oriol A, et al. · Br J Haematol · 2021 · Derived
    PubMed: PMID 33822368 · NCT02076009 · Multiple Myeloma
  19. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
    Pillarisetti K, Powers G, Luistro L, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 32956453 · NCT04108195 · Multiple Myeloma
  20. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
    Pierceall WE, Amatangelo MD, Bahlis NJ, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 32928795 · NCT01946477 (POM MM 014) · Multiple Myeloma
  21. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
    Perrot A, Facon T, Plesner T, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33326255 · NCT02252172 · Multiple Myeloma
  22. High-risk myeloma: a challenge to define and to determine the optimal treatment.
    Pawlyn C · Lancet Haematol · 2021 · Derived
    PubMed: PMID 33357481 · NCT03606577 (IFM 2018-04) · Multiple Myeloma
  23. Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation.
    Mohan M, Hari P, Szabo A, et al. · Leuk Res · 2021 · Derived
    PubMed: PMID 34182226 · NCT04140162 · Multiple Myeloma
  24. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
    Mateos MV, Spencer A, Nooka AK, et al. · Haematologica · 2021 · Derived
    PubMed: PMID 31221782 · NCT02076009 · Multiple Myeloma
  25. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.
    Leleu X, Beksac M, Chou T, et al. · Leuk Lymphoma · 2021 · Derived
    PubMed: PMID 33112184 · NCT01998971 · Multiple Myeloma
  26. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab.
    Krishnan A, Adhikarla V, Poku EK, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 33095874 · NCT03311828 · Multiple Myeloma
  27. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
    Knop S, Mateos MV, Dimopoulos MA, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 34078314 · NCT02195479 · Multiple Myeloma
  28. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E, Palladini G, Minnema MC, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 34192431 · NCT03201965 · Amyloidosis
  29. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
    Hulin C, Offner F, Moreau P, et al. · Haematologica · 2021 · Derived
    PubMed: PMID 33657786 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  30. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
    Ferris RL, Spanos WC, Leidner R, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 34083421 · NCT02488759 (CheckMate358)
  31. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
    Facon T, Kumar SK, Plesner T, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34655533 · NCT02252172 · Multiple Myeloma
  32. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA, Terpos E, Boccadoro M, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34087126 · NCT03180736 (EMN14) · Multiple Myeloma
  33. Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma.
    Crusoé EQ, Pimenta FCF, Maiolino A, et al. · Hematol Transfus Cell Ther · 2021 · Derived
    PubMed: PMID 32967807 · NCT02477891 · Multiple Myeloma
  34. Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.
    Cook G, Corso A, Streetly M, et al. · Oncol Ther · 2021 · Derived
    PubMed: PMID 33630275 · NCT02477891 · Multiple Myeloma
  35. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
    Cohen YC, Zada M, Wang SY, et al. · Nat Med · 2021 · Derived
    PubMed: PMID 33619369 · NCT04065789 (KyDaR) · Multiple Myeloma
  36. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
    Chari A, Munder M, Weisel K, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 33474705 · NCT02316106 · Multiple Myeloma
  37. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ, Baz R, Harrison SJ, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34388020 · NCT03314181 · Multiple Myeloma
  38. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
    Avet-Loiseau H, San-Miguel J, Casneuf T, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33513030 · NCT02076009 · Multiple Myeloma
  39. Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins.
    Zou P, Wang F, Wang J, et al. · J Control Release · 2021 · Background
    PubMed: PMID 34186147 · NCT07075510 · Neoplasms, Plasma Cell
  40. Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma.
    Zamagni E, Nanni C, Dozza L, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 33151787 · NCT05849610 (GEM-TECTAL)
  41. Multiple myeloma.
    van de Donk NWCJ, Pawlyn C, Yong KL, et al. · Lancet · 2021 · Background
    PubMed: PMID 33516340 · NCT05849610 (GEM-TECTAL)
  42. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.
    Suzuki K, Min CK, Kim K, et al. · Int J Hematol · 2021 · Background
    PubMed: PMID 34410635 · NCT03158688 (CANDOR) · Multiple Myeloma
  43. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
    San-Miguel J, Usmani SZ, Mateos MV, et al. · Haematologica · 2021 · Background
    PubMed: PMID 32354874 · NCT05849610 (GEM-TECTAL)
  44. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
    Quach H, Nooka A, Samoylova O, et al. · Br J Haematol · 2021 · Background
    PubMed: PMID 34046887 · NCT03158688 (CANDOR) · Multiple Myeloma
  45. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
    Munshi NC, Anderson LD, Shah N, et al. · N Engl J Med · 2021 · Background
    PubMed: PMID 33626253 · NCT05849610 (GEM-TECTAL)
  46. Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis.
    Mohyuddin GR, Aziz M, McClune B, et al. · Eur J Haematol · 2021 · Background
    PubMed: PMID 31880853 · NCT05849610 (GEM-TECTAL)
  47. Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review.
    Migdady Y, Ediriwickrema A, Jackson RP, et al. · Blood Adv · 2021 · Background
    PubMed: PMID 32119735 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  48. Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients.
    Jain D, Rajab A, Young JS, et al. · Am J Transplant · 2021 · Background
    PubMed: PMID 32243663 · NCT05145296 (COMBAT)
  49. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
    Goicoechea I, Puig N, Cedena MT, et al. · Blood · 2021 · Background
    PubMed: PMID 32693406 · NCT05849610 (GEM-TECTAL)
  50. Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Fulcher J, Berardi P, Christou G, et al. · Leuk Lymphoma · 2021 · Background
    PubMed: PMID 33749497 · NCT05289687 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  51. Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
    Frerichs KA, Broekmans MEC, Marin Soto JA, et al. · Clin Cancer Res · 2021 · Background
    PubMed: PMID 31969333 · NCT05849610 (GEM-TECTAL)
  52. Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition.
    Alishetti S, Farr M, Jennings D, et al. · Am J Transplant · 2021 · Background
    PubMed: PMID 32506824 · NCT05145296 (COMBAT)

2020 (38 papers)

  1. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.
    Ofran Y, Ringelstein-Harlev S, Slouzkey I, et al. · Leukemia · 2020 · Trial result
    PubMed: PMID 31435023 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. Will Daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia?
    Mirgh S, Ahmed R, Agrawal N, et al. · Br J Haematol · 2020 · Trial result
    PubMed: PMID 31452197 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  3. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.
    Boyle EM, Leleu X, Petillon MO, et al. · Br J Haematol · 2020 · Trial result
    PubMed: PMID 31218679 · NCT02626481 (IFM2014-04) · Multiple Myeloma
  4. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
    Xu XS, Moreau P, Usmani SZ, et al. · Adv Ther · 2020 · Derived
    PubMed: PMID 32078124 · NCT01998971 · Multiple Myeloma
  5. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
    Usmani SZ, Nahi H, Plesner T, et al. · Lancet Haematol · 2020 · Derived
    PubMed: PMID 32470437 · NCT01985126 · Multiple Myeloma
  6. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
    Usmani SZ, Nahi H, Mateos MV, et al. · Blood · 2020 · Derived
    PubMed: PMID 31270103 · NCT02519452 · Multiple Myeloma
  7. Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.
    Takamatsu H, Iida S, Shibayama H, et al. · Int J Hematol · 2020 · Derived
    PubMed: PMID 32002821 · NCT02918331 · Multiple Myeloma
  8. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
    Siegel DS, Schiller GJ, Song KW, et al. · Br J Haematol · 2020 · Derived
    PubMed: PMID 31588567 · NCT01946477 (POM MM 014) · Multiple Myeloma
  9. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
    Sanchorawala V, Sarosiek S, Schulman A, et al. · Blood · 2020 · Derived
    PubMed: PMID 31978210 · NCT02841033 · Immunoglobulin Light-chain Amyloidosis
  10. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G, Gopal AK, Minnema MC, et al. · Clin Lymphoma Myeloma Leuk · 2020 · Derived
    PubMed: PMID 30795996 · NCT02413489 · Lymphoma, Large B-Cell, Diffuse
  11. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
    Roussel M, Moreau P, Hebraud B, et al. · Lancet Haematol · 2020 · Derived
    PubMed: PMID 33242444 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  12. CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.
    O'Dwyer M, Henderson R, Naicker SD, et al. · Blood Adv · 2020 · Derived
    PubMed: PMID 31201169 · NCT02955810 (CyBorD-Dara) · Multiple Myeloma
  13. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
    Naumann RW, Hollebecque A, Meyer T, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 31487218 · NCT02488759 (CheckMate358)
  14. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
    Mateos MV, Cavo M, Blade J, et al. · Lancet · 2020 · Derived
    PubMed: PMID 31836199 · NCT02195479 · Multiple Myeloma
  15. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
    Landgren CO, Chari A, Cohen YC, et al. · Leukemia · 2020 · Derived
    PubMed: PMID 32024950 · NCT02316106 · Multiple Myeloma
  16. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A, Martinez-Lopez J, Mateos MV, et al. · Blood · 2020 · Derived
    PubMed: PMID 31113777 · NCT01998971 · Multiple Myeloma
  17. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC, Stevenaert F, Krejcik J, et al. · Cytometry A · 2020 · Derived
    PubMed: PMID 30536810 · NCT01985126 · Multiple Myeloma
  18. Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
    Vogiatzi F, Winterberg D, Lenk L, et al. · Blood · 2020 · Background
    PubMed: PMID 31311816 · NCT05289687 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  19. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
    Smith EL, Harrington K, Staehr M, et al. · Sci Transl Med · 2020 · Background
    PubMed: PMID 30918115 · NCT05849610 (GEM-TECTAL)
  20. T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol.
    Quist-Paulsen P, Toft N, Heyman M, et al. · Leukemia · 2020 · Background
    PubMed: PMID 31611626 · NCT05289687 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  21. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
    Pillarisetti K, Edavettal S, Mendonça M, et al. · Blood · 2020 · Background
    PubMed: PMID 32040549 · NCT05849610 (GEM-TECTAL)
  22. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
    Paiva B, Puig N, Cedena MT, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31770060 · NCT05849610 (GEM-TECTAL)
  23. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.
    Ostendorf L, Burns M, Durek P, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32937047 · NCT04810754 (DARALUP) · Lupus Erythematosus, Systemic
  24. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    Mateos MV, Nahi H, Legiec W, et al. · Lancet Haematol · 2020 · Background
    PubMed: PMID 32213342 · NCT05849610 (GEM-TECTAL)
  25. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S, Lee HC, Badros A, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 31859245 · NCT05849610 (GEM-TECTAL)
  26. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
    Lee DW, Santomasso BD, Locke FL, et al. · Biol Blood Marrow Transplant · 2020 · Background
    PubMed: PMID 30592986 · NCT05849610 (GEM-TECTAL)
  27. Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use.
    Kwun J, Matignon M, Manook M, et al. · J Am Soc Nephrol · 2020 · Background
    PubMed: PMID 31227636 · NCT05145296 (COMBAT)
  28. Measuring alloantibodies: a matter of quantity and quality.
    Kiernan JJ, Ellison CA, Tinckam KJ, et al. · Curr Opin Organ Transplant · 2020 · Background
    PubMed: PMID 30507703 · NCT05145296 (COMBAT)
  29. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.
    Hill QA, Hill A, Berentsen S, et al. · Blood Adv · 2020 · Background
    PubMed: PMID 31235526 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  30. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
    Facon T, Dimopoulos MA, Meuleman N, et al. · Leukemia · 2020 · Background
    PubMed: PMID 31427722 · NCT05527340 · Multiple Myeloma
  31. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia.
    Even-Or E, Naser Eddin A, Shadur B, et al. · Pediatr Blood Cancer · 2020 · Background
    PubMed: PMID 31544339 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  32. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
    Durie BGM, Kumar SK, Usmani SZ, et al. · Am J Hematol · 2020 · Background
    PubMed: PMID 32804408 · NCT05527340 · Multiple Myeloma
  33. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
    Drayson MT, Bowcock S, Planche T, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 31668592 · NCT05849610 (GEM-TECTAL)
  34. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M, Quach H, Mateos MV, et al. · Lancet · 2020 · Background
    PubMed: PMID 32682484 · NCT03158688 (CANDOR) · Multiple Myeloma
  35. Post-allogeneic transplant Evans syndrome successfully treated with daratumumab.
    Blennerhassett R, Sudini L, Gottlieb D, et al. · Br J Haematol · 2020 · Background
    PubMed: PMID 31441030 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  36. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
    Bjorklund CC, Kang J, Amatangelo M, et al. · Leukemia · 2020 · Background
    PubMed: PMID 31719682 · NCT05527340 · Multiple Myeloma
  37. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
    Belotti A, Ribolla R, Cancelli V, et al. · Am J Hematol · 2020 · Background
    PubMed: PMID 32242970 · NCT05527340 · Multiple Myeloma
  38. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
    Bahlis NJ, Dimopoulos MA, White DJ, et al. · Leukemia · 2020 · Background
    PubMed: PMID 32001798 · NCT05527340 · Multiple Myeloma

2019 (22 papers)

  1. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis.
    Shen Z, Gu X, Mao W, et al. · BMC Cancer · 2019 · Trial result
    PubMed: PMID 30037340 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
    Moreau P, Attal M, Hulin C, et al. · Lancet · 2019 · Trial result
    PubMed: PMID 31171419 · NCT02541383 (Cassiopeia) · Multiple Myeloma
  3. Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.
    Lancman G, Arinsburg S, Jhang J, et al. · Front Immunol · 2019 · Trial result
    PubMed: PMID 30498492 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  4. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N, Dombret H, Bonifacio M, et al. · Blood · 2019 · Trial result
    PubMed: PMID 29358182 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  5. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
    Bride KL, Vincent TL, Im SY, et al. · Blood · 2019 · Trial result
    PubMed: PMID 29305553 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  6. Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
    Bonda A, Punatar S, Gokarn A, et al. · Bone Marrow Transplant · 2019 · Trial result
    PubMed: PMID 29884853 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  7. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
    Overman MJ, Lonardi S, Wong KYM, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29355075 · NCT02060188 (CheckMate142)
  8. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
    Facon T, Kumar S, Plesner T, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31141632 · NCT02252172 · Multiple Myeloma
  9. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
    Bahlis NJ, Sutherland H, White D, et al. · Blood · 2019 · Derived
    PubMed: PMID 30352784 · NCT02343042 (STOMP) · Multiple Myeloma
  10. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J, Wells D, Hiatt JB, et al. · J Immunother Cancer · 2019 · Derived
    PubMed: PMID 30170630 · NCT02488759 (CheckMate358)
  11. A call to action-The transplant recipient's expectation of precision in transplant medicine.
    Wiebe C, Tambur A, Nickerson PW, et al. · Am J Transplant · 2019 · Background
    PubMed: PMID 30022602 · NCT05145296 (COMBAT)
  12. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.
    Schuetz C, Hoenig M, Moshous D, et al. · Blood Adv · 2019 · Background
    PubMed: PMID 30291113 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  13. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
    O'Donnell EK, Laubach JP, Yee AJ, et al. · Br J Haematol · 2019 · Background
    PubMed: PMID 29740809 · NCT04009109 · Multiple Myeloma
  14. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
    Moreno L, Perez C, Zabaleta A, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 30692097 · NCT05145296 (COMBAT)
  15. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
    Matyskiela ME, Zhang W, Man HW, et al. · J Med Chem · 2019 · Background
    PubMed: PMID 28425720 · NCT05527340 · Multiple Myeloma
  16. A multicolour HLA-specific B-cell FluoroSpot assay to functionally track circulating HLA-specific memory B cells.
    Luque S, Lúcia M, Crespo E, et al. · J Immunol Methods · 2019 · Background
    PubMed: PMID 30075182 · NCT05145296 (COMBAT)
  17. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk.
    Leibler C, Thiolat A, Hénique C, et al. · J Am Soc Nephrol · 2019 · Background
    PubMed: PMID 29321143 · NCT05145296 (COMBAT)
  18. Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates.
    Kwun J, Burghuber C, Manook M, et al. · Blood Adv · 2019 · Background
    PubMed: PMID 29296858 · NCT05145296 (COMBAT)
  19. [Cereblon as a primary target of IMiDs].
    Ito T, Handa H · Rinsho Ketsueki · 2019 · Background
    PubMed: PMID 31597822 · NCT05527340 · Multiple Myeloma
  20. Being Thoughtful about Desensitization.
    Formica RN, Kulkarni S · Clin J Am Soc Nephrol · 2019 · Background
    PubMed: PMID 28974523 · NCT05145296 (COMBAT)
  21. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
    Dimopoulos MA, San-Miguel J, Belch A, et al. · Haematologica · 2019 · Background
    PubMed: PMID 30237262 · NCT05527340 · Multiple Myeloma
  22. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
    Bray RA, Gebel HM, Townsend R, et al. · Am J Transplant · 2019 · Background
    PubMed: PMID 29573335 · NCT05145296 (COMBAT)

2018 (12 papers)

  1. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Blair HA · Drugs · 2018 · Trial result
    PubMed: PMID 29127588 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
    Mateos MV, Dimopoulos MA, Cavo M, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 29231133 · NCT02195479 · Multiple Myeloma
  3. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
    Krejcik J, Frerichs KA, Nijhof IS, et al. · Clin Cancer Res · 2018 · Derived
    PubMed: PMID 29025767 · NCT01615029 · Multiple Myeloma
  4. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
    Iida S, Ichinohe T, Shinagawa A, et al. · Int J Hematol · 2018 · Derived
    PubMed: PMID 29260507 · NCT02497378 · Multiple Myeloma
  5. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis.
    Sun CY, Li JY, Chu ZB, et al. · Biosci Rep · 2018 · Background
    PubMed: PMID 28706008 · NCT05218603 · Multiple Myeloma
  6. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
    Pelligra CG, Parikh K, Guo S, et al. · Clin Ther · 2018 · Background
    PubMed: PMID 28967482 · NCT01946477 (POM MM 014) · Multiple Myeloma
  7. Management of multiple myeloma in the newly diagnosed patient.
    Mateos MV, San Miguel JF · Hematology Am Soc Hematol Educ Program · 2018 · Background
    PubMed: PMID 29222298 · NCT05527340 · Multiple Myeloma
  8. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE, Shah JJ, Lee HC, et al. · Lancet Haematol · 2018 · Background
    PubMed: PMID 30501870 · NCT04009109 · Multiple Myeloma
  9. Antibody-Mediated Rejection of Solid-Organ Allografts.
    Loupy A, Lefaucheur C · N Engl J Med · 2018 · Background
    PubMed: PMID 30231232 · NCT05145296 (COMBAT)
  10. Multiple myeloma.
    Kumar SK, Rajkumar V, Kyle RA, et al. · Nat Rev Dis Primers · 2018 · Background
    PubMed: PMID 28726797 · NCT05218603 · Multiple Myeloma
  11. Further psychometric validation of the GAH scale: Responsiveness and effect size.
    Cruz-Jentoft AJ, González B, de la Rubia J, et al. · J Geriatr Oncol · 2018 · Background
    PubMed: PMID 28017687 · NCT05527340 · Multiple Myeloma
  12. Progress and Paradigms in Multiple Myeloma.
    Anderson KC · Clin Cancer Res · 2018 · Background
    PubMed: PMID 28151709 · NCT05218603 · Multiple Myeloma

2017 (21 papers)

  1. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
    Usmani SZ, Weiss BM, Plesner T, et al. · Blood · 2017 · Trial result
    PubMed: PMID 27216216 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. T-cell acute lymphoblastic leukemia.
    Raetz EA, Teachey DT · Hematology Am Soc Hematol Educ Program · 2017 · Trial result
    PubMed: PMID 27913532 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  3. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.
    Brammer JE, Saliba RM, Jorgensen JL, et al. · Bone Marrow Transplant · 2017 · Trial result
    PubMed: PMID 27618682 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  4. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
    Berry DA, Zhou S, Higley H, et al. · JAMA Oncol · 2017 · Trial result
    PubMed: PMID 28494052 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  5. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Plesner T, Arkenau HT, Gimsing P, et al. · Blood · 2017 · Derived
    PubMed: PMID 27531679 · NCT01615029 · Multiple Myeloma
  6. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
    Overman MJ, McDermott R, Leach JL, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28734759 · NCT02060188 (CheckMate142)
  7. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
    Nijhof IS, Casneuf T, van Velzen J, et al. · Blood · 2017 · Derived
    PubMed: PMID 27307294 · NCT01985126 · Multiple Myeloma
  8. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
    Lesokhin AM, Ansell SM, Armand P, et al. · J Clin Oncol · 2017 · Derived
    PubMed: PMID 27269947 · NCT01592370 · Multiple Myeloma
  9. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
    Kumar SK, LaPlant BR, Reeder CB, et al. · Blood · 2017 · Derived
    PubMed: PMID 27702799 · NCT01415882 · Multiple Myeloma
  10. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA, Oriol A, Nahi H, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 27705267 · NCT02076009 · Multiple Myeloma
  11. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
    Chari A, Suvannasankha A, Fay JW, et al. · Blood · 2017 · Derived
    PubMed: PMID 28637662 · NCT01998971 · Multiple Myeloma
  12. Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation: Delayed CTLA4-Ig Treatment Prevents Memory Alloreactive B-Cell Generation.
    Yang J, Chen J, Young JS, et al. · Transplantation · 2017 · Background
    PubMed: PMID 27362308 · NCT05145296 (COMBAT)
  13. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
    Sonneveld P, Avet-Loiseau H, Lonial S, et al. · Blood · 2017 · Background
    PubMed: PMID 27002115 · NCT05849610 (GEM-TECTAL)
  14. 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody.
    Moreno Gonzales MA, Gandhi MJ, Schinstock CA, et al. · Transplantation · 2017 · Background
    PubMed: PMID 27379560 · NCT05145296 (COMBAT)
  15. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
    Lahuerta JJ, Paiva B, Vidriales MB, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28498784 · NCT05849610 (GEM-TECTAL)
  16. Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients.
    Kwun J, Burghuber C, Manook M, et al. · J Am Soc Nephrol · 2017 · Background
    PubMed: PMID 28232617 · NCT05145296 (COMBAT)
  17. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
    Kumar S, Paiva B, Anderson KC, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27511158 · NCT05218603 · Multiple Myeloma
  18. Cancer Treatment as an Accelerated Aging Process: Assessment, Biomarkers, and Interventions.
    Hurria A, Jones L, Muss HB, et al. · Am Soc Clin Oncol Educ Book · 2017 · Background
    PubMed: PMID 27249761 · NCT04009109 · Multiple Myeloma
  19. How I treat autoimmune hemolytic anemia.
    Go RS, Winters JL, Kay NE, et al. · Blood · 2017 · Background
    PubMed: PMID 28360039 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  20. How I manage the toxicities of myeloma drugs.
    Delforge M, Ludwig H · Blood · 2017 · Background
    PubMed: PMID 28275090 · NCT05849610 (GEM-TECTAL)
  21. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.
    Chapuy CI, Aguad MD, Nicholson RT, et al. · Transfusion · 2017 · Background
    PubMed: PMID 27600566 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic

2016 (13 papers)

  1. Monoclonal antibodies in myeloma.
    Sondergeld P, van de Donk NW, Richardson PG, et al. · Clin Adv Hematol Oncol · 2016 · Trial result
    PubMed: PMID 26452191 · NCT03792620 (MAXDARA) · Multiple Myeloma
  2. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
    Lonial S, Weiss BM, Usmani SZ, et al. · Lancet · 2016 · Trial result
    PubMed: PMID 26778538 · NCT03792620 (MAXDARA) · Multiple Myeloma
  3. CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
    Laubach JP, Richardson PG · Clin Cancer Res · 2016 · Trial result
    PubMed: PMID 25878332 · NCT03792620 (MAXDARA) · Multiple Myeloma
  4. The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.
    Franssen LE, van de Donk NW, Emmelot ME, et al. · Bone Marrow Transplant · 2016 · Trial result
    PubMed: PMID 25798669 · NCT02419118 (DARA) · Multiple Myeloma
  5. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Palumbo A, Chanan-Khan A, Weisel K, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27557302 · NCT02136134 · Multiple Myeloma
  6. Belatacept and Long-Term Outcomes in Kidney Transplantation.
    Vincenti F, Rostaing L, Grinyo J, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 26816011 · NCT05145296 (COMBAT)
  7. Defining and treating high-risk multiple myeloma.
    Usmani SZ, Rodriguez-Otero P, Bhutani M, et al. · Leukemia · 2016 · Background
    PubMed: PMID 26265183 · NCT05849610 (GEM-TECTAL)
  8. Targeting B-cell maturation antigen in multiple myeloma.
    Tai YT, Anderson KC · Immunotherapy · 2016 · Background
    PubMed: PMID 26370838 · NCT05849610 (GEM-TECTAL)
  9. Cancer statistics, 2016.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2016 · Background
    PubMed: PMID 26742998 · NCT04009109 · Multiple Myeloma
  10. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
    Nijhof IS, Groen RW, Lokhorst HM, et al. · Leukemia · 2016 · Background
    PubMed: PMID 25975191 · NCT04700176 · Multiple Myeloma
  11. Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation.
    Lúcia M, Luque S, Crespo E, et al. · Kidney Int · 2016 · Background
    PubMed: PMID 26176829 · NCT05145296 (COMBAT)
  12. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year.
    Cornell LD, Schinstock CA, Gandhi MJ, et al. · Am J Transplant · 2016 · Background
    PubMed: PMID 25731800 · NCT05145296 (COMBAT)
  13. Practical review of immunizations in adult patients with cancer.
    Ariza-Heredia EJ, Chemaly RF · Hum Vaccin Immunother · 2016 · Background
    PubMed: PMID 26110220 · NCT05849610 (GEM-TECTAL)

2015 (18 papers)

  1. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.
    van Dongen JJ, van der Velden VH, Brüggemann M, et al. · Blood · 2015 · Trial result
    PubMed: PMID 25999452 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
    Rajkumar SV, Dimopoulos MA, Palumbo A, et al. · Lancet Oncol · 2015 · Trial result
    PubMed: PMID 25439696 · NCT03792620 (MAXDARA) · Multiple Myeloma
  3. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.
    Phipps C, Chen Y, Gopalakrishnan S, et al. · Ther Adv Hematol · 2015 · Trial result
    PubMed: PMID 26137203 · NCT03792620 (MAXDARA) · Multiple Myeloma
  4. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
    Overdijk MB, Verploegen S, Bögels M, et al. · MAbs · 2015 · Trial result
    PubMed: PMID 25760767 · NCT02419118 (DARA) · Multiple Myeloma
  5. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
    Lokhorst HM, Plesner T, Laubach JP, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 26308596 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  6. How I treat T-cell acute lymphoblastic leukemia in adults.
    Litzow MR, Ferrando AA · Blood · 2015 · Trial result
    PubMed: PMID 25966987 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  7. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM, Lesokhin AM, Borrello I, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 25482239 · NCT01592370 · Multiple Myeloma
  8. Treatment of autoimmune hemolytic anemias.
    Zanella A, Barcellini W · Haematologica · 2015 · Background
    PubMed: PMID 25271314 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  9. Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
    Sonneveld P, Asselbergs E, Zweegman S, et al. · Blood · 2015 · Background
    PubMed: PMID 25398935 · NCT03992170 (DART4MM) · Multiple Myeloma
  10. Multiple myeloma.
    Röllig C, Knop S, Bornhäuser M, et al. · Lancet · 2015 · Background
    PubMed: PMID 25540889 · NCT05218603 · Multiple Myeloma
  11. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
    Reynaud Q, Durieu I, Dutertre M, et al. · Autoimmun Rev · 2015 · Background
    PubMed: PMID 25497766 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  12. UK Renal Registry 16th annual report: chapter 4 demography of patients waitlisted for renal transplantation in the UK: national and centre-specific analyses.
    Pruthi R, Hilton R, Pankhurst L, et al. · Nephron Clin Pract · 2015 · Background
    PubMed: PMID 24662168 · NCT05145296 (COMBAT)
  13. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
    Palumbo A, Avet-Loiseau H, Oliva S, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 26240224 · NCT05849610 (GEM-TECTAL)
  14. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
    Paller CJ, Bradbury PA, Ivy SP, et al. · Clin Cancer Res · 2015 · Background
    PubMed: PMID 25125258 · NCT05145296 (COMBAT)
  15. Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells.
    Leibler C, Matignon M, Pilon C, et al. · Am J Transplant · 2015 · Background
    PubMed: PMID 24730563 · NCT05145296 (COMBAT)
  16. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK, Berdeja JG, Niesvizky R, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25456369 · NCT04009109 · Multiple Myeloma
  17. Diagnosis and management of antibody-mediated rejection: current status and novel approaches.
    Djamali A, Kaufman DB, Ellis TM, et al. · Am J Transplant · 2015 · Background
    PubMed: PMID 24401076 · NCT05145296 (COMBAT)
  18. Promising therapies in multiple myeloma.
    Bianchi G, Richardson PG, Anderson KC, et al. · Blood · 2015 · Background
    PubMed: PMID 26031917 · NCT05218603 · Multiple Myeloma

2014 (13 papers)

  1. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
    van de Donk NW, Lokhorst HM · Expert Opin Pharmacother · 2014 · Trial result
    PubMed: PMID 23721099 · NCT03792620 (MAXDARA) · Multiple Myeloma
  2. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A, Bringhen S, Larocca A, et al. · J Clin Oncol · 2014 · Background
    PubMed: PMID 24449241 · NCT05218603 · Multiple Myeloma
  3. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
    Palumbo A, Bringhen S, Kumar SK, et al. · Lancet Oncol · 2014 · Background
    PubMed: PMID 24525202 · NCT05218603 · Multiple Myeloma
  4. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).
    Ocio EM, Richardson PG, Rajkumar SV, et al. · Leukemia · 2014 · Background
    PubMed: PMID 24253022 · NCT03992170 (DART4MM) · Multiple Myeloma
  5. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
    McCarthy PL, Einsele H, Attal M, et al. · Expert Rev Hematol · 2014 · Background
    PubMed: PMID 24471885 · NCT05218603 · Multiple Myeloma
  6. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.
    Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. · Blood · 2014 · Background
    PubMed: PMID 24646471 · NCT05218603 · Multiple Myeloma
  7. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
    Ladetto M, Brüggemann M, Monitillo L, et al. · Leukemia · 2014 · Background
    PubMed: PMID 24342950 · NCT05218603 · Multiple Myeloma
  8. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
    Kumar SK, Dispenzieri A, Lacy MQ, et al. · Leukemia · 2014 · Background
    PubMed: PMID 24157580 · NCT04009109 · Multiple Myeloma
  9. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection.
    Kim EJ, Kwun J, Gibby AC, et al. · Am J Transplant · 2014 · Background
    PubMed: PMID 24354871 · NCT05145296 (COMBAT)
  10. Robust isolation of malignant plasma cells in multiple myeloma.
    Frigyesi I, Adolfsson J, Ali M, et al. · Blood · 2014 · Background
    PubMed: PMID 24385542 · NCT05849610 (GEM-TECTAL)
  11. Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig.
    Chen J, Yin H, Xu J, et al. · Am J Transplant · 2014 · Background
    PubMed: PMID 23855587 · NCT05145296 (COMBAT)
  12. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
    Benboubker L, Dimopoulos MA, Dispenzieri A, et al. · N Engl J Med · 2014 · Background
    PubMed: PMID 25184863 · NCT04009109 · Multiple Myeloma
  13. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
    Beldjord K, Chevret S, Asnafi V, et al. · Blood · 2014 · Background
    PubMed: PMID 24740809 · NCT05289687 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

2013 (10 papers)

  1. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
    Yang B, Yu RL, Chi XH, et al. · PLoS One · 2013 · Background
    PubMed: PMID 23691202 · NCT05218603 · Multiple Myeloma
  2. Predicting relapse risk in childhood acute lymphoblastic leukaemia.
    Teachey DT, Hunger SP · Br J Haematol · 2013 · Background
    PubMed: PMID 23808872 · NCT05289687 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  3. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
    Mateos MV, Oriol A, Martínez-López J, et al. · Blood · 2013 · Background
    PubMed: PMID 22889759 · NCT05218603 · Multiple Myeloma
  4. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.
    Labrijn AF, Meesters JI, de Goeij BE, et al. · Proc Natl Acad Sci U S A · 2013 · Background
    PubMed: PMID 23479652 · NCT05849610 (GEM-TECTAL)
  5. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.
    Chillemi A, Zaccarello G, Quarona V, et al. · Mol Med · 2013 · Background
    PubMed: PMID 23615966 · NCT04700176 · Multiple Myeloma
  6. Initial treatment of nontransplant patients with multiple myeloma.
    Cerrato C, Palumbo A · Semin Oncol · 2013 · Background
    PubMed: PMID 24135402 · NCT03992170 (DART4MM) · Multiple Myeloma
  7. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO, Evbuomwan MO, Pittaluga S, et al. · Clin Cancer Res · 2013 · Background
    PubMed: PMID 23344265 · NCT05849610 (GEM-TECTAL)
  8. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
    Birgens H, Frederiksen H, Hasselbalch HC, et al. · Br J Haematol · 2013 · Background
    PubMed: PMID 23981017 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  9. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
    Bergsagel PL, Mateos MV, Gutierrez NC, et al. · Blood · 2013 · Background
    PubMed: PMID 23165477 · NCT05849610 (GEM-TECTAL)
  10. Multiple myeloma: an update.
    Al-Farsi K · Oman Med J · 2013 · Background
    PubMed: PMID 23386937 · NCT05218603 · Multiple Myeloma

2012 (15 papers)

  1. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
    Morgan GJ, Davies FE, Gregory WM, et al. · Haematologica · 2012 · Trial result
    PubMed: PMID 22058209 · NCT03792620 (MAXDARA) · Multiple Myeloma
  2. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.
    Gökbuget N, Kneba M, Raff T, et al. · Blood · 2012 · Trial result
    PubMed: PMID 22442346 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  3. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22802322 · NCT03992170 (DART4MM) · Multiple Myeloma
  4. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L, Oriol A, Teruel AI, et al. · Blood · 2012 · Background
    PubMed: PMID 22791289 · NCT03992170 (DART4MM) · Multiple Myeloma
  5. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
    Morgan GJ, Gregory WM, Davies FE, et al. · Blood · 2012 · Background
    PubMed: PMID 22021371 · NCT05218603 · Multiple Myeloma
  6. IMWG consensus on maintenance therapy in multiple myeloma.
    Ludwig H, Durie BG, McCarthy P, et al. · Blood · 2012 · Background
    PubMed: PMID 22271445 · NCT05218603 · Multiple Myeloma
  7. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
    Kumar SK, Lee JH, Lahuerta JJ, et al. · Leukemia · 2012 · Background
    PubMed: PMID 21799510 · NCT04700176 · Multiple Myeloma
  8. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
    Kumar S, Flinn I, Richardson PG, et al. · Blood · 2012 · Background
    PubMed: PMID 22422823 · NCT03992170 (DART4MM) · Multiple Myeloma
  9. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
    Klinger M, Brandl C, Zugmaier G, et al. · Blood · 2012 · Background
    PubMed: PMID 22592608 · NCT05849610 (GEM-TECTAL)
  10. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
    Jakubowiak AJ, Dytfeld D, Griffith KA, et al. · Blood · 2012 · Background
    PubMed: PMID 22665938 · NCT03992170 (DART4MM) · Multiple Myeloma
  11. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.
    Hunger SP, Lu X, Devidas M, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22412151 · NCT05289687 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  12. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.
    Gozzetti A, Cerase A, Lotti F, et al. · Cancer · 2012 · Background
    PubMed: PMID 21932386 · NCT03992170 (DART4MM) · Multiple Myeloma
  13. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.
    Dores GM, Devesa SS, Curtis RE, et al. · Blood · 2012 · Background
    PubMed: PMID 22086414 · NCT05289687 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  14. A guide to rational dosing of monoclonal antibodies.
    Bai S, Jorga K, Xin Y, et al. · Clin Pharmacokinet · 2012 · Background
    PubMed: PMID 22257150 · NCT05849610 (GEM-TECTAL)
  15. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma.
    Atamaniuk J, Gleiss A, Porpaczy E, et al. · Eur J Clin Invest · 2012 · Background
    PubMed: PMID 22591013 · NCT05849610 (GEM-TECTAL)

2011 (14 papers)

  1. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
    Schrappe M, Valsecchi MG, Bartram CR, et al. · Blood · 2011 · Trial result
    PubMed: PMID 21719599 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. Multiple myeloma.
    Palumbo A, Anderson K · N Engl J Med · 2011 · Trial result
    PubMed: PMID 21410373 · NCT03792620 (MAXDARA) · Multiple Myeloma
  3. Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication.
    J Pharmacol Pharmacother · 2011 · Background
    PubMed: PMID 21808590 · NCT05218603 · Multiple Myeloma
  4. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
    Rajkumar SV, Harousseau JL, Durie B, et al. · Blood · 2011 · Background
    PubMed: PMID 21292775 · NCT05218603 · Multiple Myeloma
  5. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Palumbo A, Bringhen S, Rossi D, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 20940200 · NCT05218603 · Multiple Myeloma
  6. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
    Morgan GJ, Davies FE, Gregory WM, et al. · Blood · 2011 · Background
    PubMed: PMID 21652683 · NCT03992170 (DART4MM) · Multiple Myeloma
  7. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.
    Moreau P, Avet-Loiseau H, Harousseau JL, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21482979 · NCT03992170 (DART4MM) · Multiple Myeloma
  8. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.
    Hurria A, Togawa K, Mohile SG, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21810685 · NCT04009109 · Multiple Myeloma
  9. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.
    Hurria A, Cirrincione CT, Muss HB, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21357782 · NCT04009109 · Multiple Myeloma
  10. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.
    Gay F, Larocca A, Wijermans P, et al. · Blood · 2011 · Background
    PubMed: PMID 21228328 · NCT03992170 (DART4MM) · Multiple Myeloma
  11. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
    Fayers PM, Palumbo A, Hulin C, et al. · Blood · 2011 · Background
    PubMed: PMID 21670471 · NCT03992170 (DART4MM) · Multiple Myeloma
  12. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M, Tacchetti P, Patriarca F, et al. · Lancet · 2011 · Background
    PubMed: PMID 21146205 · NCT03992170 (DART4MM) · Multiple Myeloma
  13. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
    Bringhen S, Larocca A, Rossi D, et al. · Blood · 2011 · Background
    PubMed: PMID 20807892 · NCT03992170 (DART4MM) · Multiple Myeloma
  14. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M, Haznedar R, Firatli-Tuglular T, et al. · Eur J Haematol · 2011 · Background
    PubMed: PMID 20942865 · NCT03992170 (DART4MM) · Multiple Myeloma

2010 (14 papers)

  1. Clinical development of novel proteasome inhibitors for cancer treatment.
    Yang H, Zonder JA, Dou QP, et al. · Expert Opin Investig Drugs · 2010 · Background
    PubMed: PMID 19505187 · NCT05218603 · Multiple Myeloma
  2. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
    Wijermans P, Schaafsma M, Termorshuizen F, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20516439 · NCT05218603 · Multiple Myeloma
  3. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
    Waage A, Gimsing P, Fayers P, et al. · Blood · 2010 · Background
    PubMed: PMID 20448107 · NCT05218603 · Multiple Myeloma
  4. How I treat multiple myeloma in younger patients.
    Stewart AK, Richardson PG, San-Miguel JF, et al. · Blood · 2010 · Background
    PubMed: PMID 19861683 · NCT03992170 (DART4MM) · Multiple Myeloma
  5. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Richardson PG, Weller E, Lonial S, et al. · Blood · 2010 · Background
    PubMed: PMID 20385792 · NCT04009109 · Multiple Myeloma
  6. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
    Reeder CB, Reece DE, Kukreti V, et al. · Blood · 2010 · Background
    PubMed: PMID 20413666 · NCT03992170 (DART4MM) · Multiple Myeloma
  7. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV, Richardson PG, Schlag R, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20368561 · NCT05218603 · Multiple Myeloma
  8. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV, Oriol A, Martínez-López J, et al. · Lancet Oncol · 2010 · Background
    PubMed: PMID 20739218 · NCT05218603 · Multiple Myeloma
  9. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
    Marks DI, Paietta EM, Moorman AV, et al. · Blood · 2010 · Background
    PubMed: PMID 19828704 · NCT05289687 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  10. How I treat autoimmune hemolytic anemias in adults.
    Lechner K, Jäger U · Blood · 2010 · Background
    PubMed: PMID 20548093 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  11. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
    Ladetto M, Pagliano G, Ferrero S, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20308672 · NCT03992170 (DART4MM) · Multiple Myeloma
  12. Cancer statistics, 2010.
    Jemal A, Siegel R, Xu J, et al. · CA Cancer J Clin · 2010 · Background
    PubMed: PMID 20610543 · NCT05218603 · Multiple Myeloma
  13. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL, Attal M, Avet-Loiseau H, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20823406 · NCT03992170 (DART4MM) · Multiple Myeloma
  14. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
    Avet-Loiseau H, Leleu X, Roussel M, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20644101 · NCT05218603 · Multiple Myeloma

2009 (2 papers)

  1. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
    Bassan R, Spinelli O, Oldani E, et al. · Blood · 2009 · Trial result
    PubMed: PMID 19141862 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C, Facon T, Rodon P, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19451428 · NCT03992170 (DART4MM) · Multiple Myeloma

2008 (9 papers)

  1. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF, Schlag R, Khuageva NK, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18753647 · NCT03992170 (DART4MM) · Multiple Myeloma
  2. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG.
    Perry DK, Pollinger HS, Burns JM, et al. · Am J Transplant · 2008 · Background
    PubMed: PMID 18184311 · NCT05145296 (COMBAT)
  3. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Palumbo A, Rajkumar SV, Dimopoulos MA, et al. · Leukemia · 2008 · Background
    PubMed: PMID 18094721 · NCT05849610 (GEM-TECTAL)
  4. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
    Palumbo A, Bringhen S, Liberati AM, et al. · Blood · 2008 · Background
    PubMed: PMID 18505783 · NCT03992170 (DART4MM) · Multiple Myeloma
  5. Multiple myeloma.
    Kyle RA, Rajkumar SV · Blood · 2008 · Background
    PubMed: PMID 18332230 · NCT03992170 (DART4MM) · Multiple Myeloma
  6. Improved survival in multiple myeloma and the impact of novel therapies.
    Kumar SK, Rajkumar SV, Dispenzieri A, et al. · Blood · 2008 · Background
    PubMed: PMID 17975015 · NCT03992170 (DART4MM) · Multiple Myeloma
  7. Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
    Faiman B, Bilotti E, Mangan PA, et al. · Clin J Oncol Nurs · 2008 · Background
    PubMed: PMID 18490257 · NCT05849610 (GEM-TECTAL)
  8. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons.
    Dimos JT, Rodolfa KT, Niakan KK, et al. · Science · 2008 · Background
    PubMed: PMID 18669821 · NCT04700176 · Multiple Myeloma
  9. Recent major improvement in long-term survival of younger patients with multiple myeloma.
    Brenner H, Gondos A, Pulte D, et al. · Blood · 2008 · Background
    PubMed: PMID 17901246 · NCT03992170 (DART4MM) · Multiple Myeloma

2007 (8 papers)

  1. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM, Chen C, Niesvizky R, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 18032763 · NCT04009109 · Multiple Myeloma
  2. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
    Richardson PG, Blood E, Mitsiades CS, et al. · Blood · 2007 · Background
    PubMed: PMID 16840727 · NCT04009109 · Multiple Myeloma
  3. Maintenance therapy in multiple myeloma.
    Mihelic R, Kaufman JL, Lonial S, et al. · Leukemia · 2007 · Background
    PubMed: PMID 17344913 · NCT05218603 · Multiple Myeloma
  4. Structure and enzymatic functions of human CD38.
    Lee HC · Mol Med · 2007 · Background
    PubMed: PMID 17380198 · NCT04700176 · Multiple Myeloma
  5. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
    Facon T, Mary JY, Hulin C, et al. · Lancet · 2007 · Background
    PubMed: PMID 17920916 · NCT03992170 (DART4MM) · Multiple Myeloma
  6. Epidemiology of autoimmune diseases in Denmark.
    Eaton WW, Rose NR, Kalaydjian A, et al. · J Autoimmun · 2007 · Background
    PubMed: PMID 17582741 · NCT05004259 (DARA-AIHA) · Anemia, Hemolytic
  7. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M, Spencer A, Attal M, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 18032762 · NCT04009109 · Multiple Myeloma
  8. Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells.
    Darce JR, Arendt BK, Chang SK, et al. · J Immunol · 2007 · Background
    PubMed: PMID 17442944 · NCT05849610 (GEM-TECTAL)

2006 (4 papers)

  1. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.
    Brüggemann M, Raff T, Flohr T, et al. · Blood · 2006 · Trial result
    PubMed: PMID 16195338 · NCT07021677 (DARA_T_ALL) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  2. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
    Palumbo A, Bringhen S, Caravita T, et al. · Lancet · 2006 · Background
    PubMed: PMID 16530576 · NCT05218603 · Multiple Myeloma
  3. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.
    Facon T, Mary JY, Pégourie B, et al. · Blood · 2006 · Background
    PubMed: PMID 16174762 · NCT04009109 · Multiple Myeloma
  4. International uniform response criteria for multiple myeloma.
    Durie BG, Harousseau JL, Miguel JS, et al. · Leukemia · 2006 · Background
    PubMed: PMID 16855634 · NCT05218603 · Multiple Myeloma

2005 (2 papers)

  1. Developing a cancer-specific geriatric assessment: a feasibility study.
    Hurria A, Gupta S, Zauderer M, et al. · Cancer · 2005 · Background
    PubMed: PMID 16206252 · NCT04009109 · Multiple Myeloma
  2. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
    Dredge K, Horsfall R, Robinson SP, et al. · Microvasc Res · 2005 · Background
    PubMed: PMID 15797261 · NCT04009109 · Multiple Myeloma

2004 (3 papers)

  1. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
    Novak AJ, Darce JR, Arendt BK, et al. · Blood · 2004 · Background
    PubMed: PMID 14512299 · NCT05849610 (GEM-TECTAL)
  2. The RAIG family member, GPRC5D, is associated with hard-keratinized structures.
    Inoue S, Nambu T, Shimomura T, et al. · J Invest Dermatol · 2004 · Background
    PubMed: PMID 15086536 · NCT05849610 (GEM-TECTAL)
  3. The proteasome: a suitable antineoplastic target.
    Adams J · Nat Rev Cancer · 2004 · Background
    PubMed: PMID 15122206 · NCT05218603 · Multiple Myeloma

2003 (3 papers)

  1. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.
    Schafer PH, Gandhi AK, Loveland MA, et al. · J Pharmacol Exp Ther · 2003 · Background
    PubMed: PMID 12649301 · NCT04009109 · Multiple Myeloma
  2. Review of 1027 patients with newly diagnosed multiple myeloma.
    Kyle RA, Gertz MA, Witzig TE, et al. · Mayo Clin Proc · 2003 · Background
    PubMed: PMID 12528874 · NCT04009109 · Multiple Myeloma
  3. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
    Fonseca R, Blood E, Rue M, et al. · Blood · 2003 · Background
    PubMed: PMID 12576322 · NCT03992170 (DART4MM) · Multiple Myeloma

2002 (3 papers)

  1. Directed differentiation of embryonic stem cells into motor neurons.
    Wichterle H, Lieberam I, Porter JA, et al. · Cell · 2002 · Background
    PubMed: PMID 12176325 · NCT04700176 · Multiple Myeloma
  2. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
    Richardson PG, Schlossman RL, Weller E, et al. · Blood · 2002 · Background
    PubMed: PMID 12384400 · NCT04009109 · Multiple Myeloma
  3. The role of retinoids and retinoic acid receptors in normal hematopoiesis.
    Collins SJ · Leukemia · 2002 · Background
    PubMed: PMID 12357341 · NCT04700176 · Multiple Myeloma

2001 (4 papers)

  1. Human CD38: a (r)evolutionary story of enzymes and receptors.
    Deaglio S, Mehta K, Malavasi F, et al. · Leuk Res · 2001 · Trial result
    PubMed: PMID 11137554 · NCT03792620 (MAXDARA) · Multiple Myeloma
  2. Fluorescence in situ hybridization: uses and limitations.
    Gozzetti A, Le Beau MM · Semin Hematol · 2001 · Background
    PubMed: PMID 11071355 · NCT03992170 (DART4MM) · Multiple Myeloma
  3. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
    Davies FE, Raje N, Hideshima T, et al. · Blood · 2001 · Background
    PubMed: PMID 11418482 · NCT04009109 · Multiple Myeloma
  4. Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D.
    Bräuner-Osborne H, Jensen AA, Sheppard PO, et al. · Biochim Biophys Acta · 2001 · Background
    PubMed: PMID 11311935 · NCT05849610 (GEM-TECTAL)

2000 (1 paper)

  1. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
    Hideshima T, Chauhan D, Shima Y, et al. · Blood · 2000 · Background
    PubMed: PMID 11049970 · NCT04009109 · Multiple Myeloma

1999 (1 paper)

  1. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
    Corral LG, Haslett PA, Muller GW, et al. · J Immunol · 1999 · Background
    PubMed: PMID 10384139 · NCT04009109 · Multiple Myeloma

1998 (1 paper)

  1. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
    Steinherz PG, Gaynon PS, Breneman JC, et al. · Cancer · 1998 · Background
    PubMed: PMID 9452280 · NCT05289687 · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

1997 (1 paper)

  1. All-trans-retinoic acid in acute promyelocytic leukemia.
    Tallman MS, Andersen JW, Schiffer CA, et al. · N Engl J Med · 1997 · Background
    PubMed: PMID 9321529 · NCT04700176 · Multiple Myeloma

1995 (1 paper)

  1. All-trans retinoic acid for advanced multiple myeloma.
    Musto P, Falcone A, Sajeva MR, et al. · Blood · 1995 · Background
    PubMed: PMID 7780162 · NCT04700176 · Multiple Myeloma

1994 (2 papers)

  1. CD34+/CD33- cells reselected from macrophage inflammatory protein 1 alpha+interleukin-3--supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture initiating cells.
    Verfaillie CM, Miller JS · Blood · 1994 · Trial result
    PubMed: PMID 7520771 · NCT03792620 (MAXDARA) · Multiple Myeloma
  2. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction.
    Ogata A, Nishimoto N, Shima Y, et al. · Blood · 1994 · Background
    PubMed: PMID 7949175 · NCT04700176 · Multiple Myeloma

1992 (2 papers)

  1. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.
    Tallman MS, Kwaan HC · Blood · 1992 · Background
    PubMed: PMID 1732003 · NCT04700176 · Multiple Myeloma
  2. A formula to estimate the approximate surface area if height and weight be known. 1916.
    Du Bois D, Du Bois EF · Nutrition · 1992 · Background
    PubMed: PMID 2520314 · NCT04661137 · Multiple Myeloma

1990 (1 paper)

  1. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship.
    Chomienne C, Ballerini P, Balitrand N, et al. · Blood · 1990 · Background
    PubMed: PMID 2224120 · NCT04700176 · Multiple Myeloma

1987 (2 papers)

  1. Simplified calculation of body-surface area.
    Mosteller RD · N Engl J Med · 1987 · Background
    PubMed: PMID 3657876 · NCT04661137 · Multiple Myeloma
  2. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
    Charlson ME, Pompei P, Ales KL, et al. · J Chronic Dis · 1987 · Background
    PubMed: PMID 3558716 · NCT03992170 (DART4MM) · Multiple Myeloma

1986 (1 paper)

  1. Acute promyelocytic leukemia. M.D. Anderson Hospital experience.
    Kantarjian HM, Keating MJ, Walters RS, et al. · Am J Med · 1986 · Background
    PubMed: PMID 3458366 · NCT04700176 · Multiple Myeloma

1985 (1 paper)

  1. Acute promyelocytic leukemia in 57 previously untreated patients.
    Cordonnier C, Vernant JP, Brun B, et al. · Cancer · 1985 · Background
    PubMed: PMID 3855265 · NCT04700176 · Multiple Myeloma

1983 (1 paper)

  1. Toxicity and response criteria of the Eastern Cooperative Oncology Group.
    Oken MM, Creech RH, Tormey DC, et al. · Am J Clin Oncol · 1983 · Background
    PubMed: PMID 7165009 · NCT04661137 · Multiple Myeloma

1980 (1 paper)

  1. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage.
    Reinherz EL, Kung PC, Goldstein G, et al. · Proc Natl Acad Sci U S A · 1980 · Trial result
    PubMed: PMID 6966400 · NCT03792620 (MAXDARA) · Multiple Myeloma

1976 (1 paper)

  1. Prediction of creatinine clearance from serum creatinine.
    Cockcroft DW, Gault MH · Nephron · 1976 · Background
    PubMed: PMID 1244564 · NCT04661137 · Multiple Myeloma

1975 (1 paper)

  1. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Pocock SJ, Simon R · Biometrics · 1975 · Background
    PubMed: PMID 1100130 · NCT04009109 · Multiple Myeloma

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).